Modalis Therapeutics has partnered with SOLVE FSHD to advance the development of an experimental epigenome-editing therapy for facioscapulohumeral...

Feng Zhang and colleagues report that the engineering of a compact RNA-guided nuclease, NovaIscB, derived from the OMEGA system enables efficient and...

Tune Therapeutics has announced regulatory approval to begin a Phase 1b trial of its chronic hepatitis B therapy in Hong Kong, marking a strategic...

Tune Therapeutics has received clinical trial application approval from the New Zealand Medicines and Medical Devices Safety Authority to initiate a...

Researchers have developed a compact, all-in-one CRISPR-dCas9-based repressor platform delivered via AAV, effectively silencing gene expression...

In a recent study, researchers in Italy addressed the critical need for experimental validation of durable epigenetic silencing after transient...

By targeting a highly conserved master controller sequence, Tune Therapeutics' lead candidate TUNE-401 can epigenetically silence all forms of the...